Medicina nuclear

1991

1. BCM-IMx and CA15.3 serum levels in patients with breast cancers. Comparative study

   Bulletin du Cancer, Vol. 78, Núm. 8, pp. 743-745

2. BCM-IMx behaviour in patients with lung diseases

   Bulletin du Cancer, Vol. 78, Núm. 9, pp. 843-845

3. CA 15.3 in nonmalignant liver diseases

   International Journal of Biological Markers, Vol. 6, Núm. 3, pp. 188-192

4. Comportamiento del factor de crecimiento epidérmico en el líquido de los quistes mamarios. Diferencias en función de los tres tipos existentes.

   Revista Clinica Espanola

5. Correlación entre las concentraciones séricas de BCM (mucina del cáncer de mama), CA549 y estradiol en mujeres afectas de macroquistes mamarios.

   Medicina Clinica

6. Correlación entre las concentraciones séricas de CA15.3 y estradiol en mujeres con enfermedad macroquística de la mama. Estudio en función del tipo de quiste.

   Revista Clinica Espanola

7. Diagnosis using monoclonal antibody imaging in the clinical follow-up of colorectal cancer

   Anales de medicina interna (Madrid, Spain : 1984), Vol. 8, Núm. 8, pp. 377-381

8. Different immunoreactivity between cyst fluid and serum prolactin in women with cystic breast disease.

   International Journal of Biological Markers

9. Evidence of a correlation between CA 15.3 and estradiol serum levels in women with fibrocystic (non macrocystic) mastopathy [2]

   International Journal of Biological Markers

10. Evidence of a correlation between CA 15.3 and prolactin serum levels after TRH administration in women with gross cystic breast disease [1]

    International Journal of Biological Markers

11. GCDFP-70 protein in cyst fluid identified as albumin and used to classify cysts in women with breast gross cystic disease

    Clinical Chemistry, Vol. 37, Núm. 4, pp. 547-551

12. High TAG-72 serum levels, defined by MoAb B72.3, in premenopausal women with benign breast disease, are associated with type I gross cystic disease.

    International Journal of Biological Markers

13. LA GAMMAGRAFIA OSEA EN LA ENFERMEDAD METASTASICA

    Revista Espanola de Medicina Nuclear, Supplement, Vol. 10, Núm. 3, pp. 23-30

14. La dosificación simultánea de SLX y CEA no incrementa la utilidad clínica de este último en pacientes con carcinoma colorrectales.

    Revista Clinica Espanola

15. Neuron-specific enolase concentrations in serum in benign liver diseases

    Clinical Chemistry, Vol. 37, Núm. 4, pp. 579-581

16. Seric BCM-RIA levels in patients with lung pathologies [4]

    International Journal of Biological Markers

17. Seric SLX values in patients with lung tumors [3]

    International Journal of Biological Markers

18. Serum BCM-IMx levels in 376 patients with non-malignant diseases.

    International Journal of Biological Markers